Hubert Borell

CYP4F Enzymes Are Responsible for the Elimination of Fingolimod (FTY720), a Novel Treatment of Relapsing Multiple Sclerosis

M. Zollinger, A. Zimmerlin, C. Patten, 2011, Drug Metabolism and Disposition.

Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite s

K. Schroer, A. Meissner, G. Camenisch, 2020 .

Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite

K. Schroer, A. Meissner, G. Camenisch, 2020, Drug Metabolism and Disposition.

In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics

G. Camenisch, M. Ufer, Felix Huth, 2017, European Journal of Clinical Pharmacology.

Metabolism and Disposition of Siponimod, a Novel Selective S1P1/S1P5 Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism

K. Schroer, E. Legangneux, A. Meissner, 2018, Drug Metabolism and Disposition.

An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data

G. Camenisch, Hilmar Schiller, Alexander David James, 2020, Pharmacology research & perspectives.

CYP4F Enzymes Are Responsible for the Elimination of Fingolimod (FTY720), a Novel Treatment of Relapsing Multiple Sclerosis

M. Zollinger, A. Zimmerlin, C. Patten, 2011, Drug Metabolism and Disposition.